Gerresheimer has forecast medium-term growth of 4-6%, with further plans to expand in the pharma sector and expand facilities in emerging markets.
“Health and well-being are issues taking on ever greater global significance. I believe we have very strong medium-term growth prospects with our products becoming increasingly important. We are outstandingly well placed with our broad product portfolio, experience and proximity to the customer. We aim to grow in promising pharma markets, develop innovative products for safe and simple drug delivery and expand local production in the main emerging economies,” said Uwe Röhrhoff, CEO of Gerresheimer AG, speaking to investors and analysts during Capital Markets Day. “We will invest heavily in production capacity as well as in standardising our technologies and in quality systems. This is the basis for healthy medium-term growth for our company.”
Röhrhoff explained the focus for the group going forward, which is centred around emerging pharma trends. “The pharma and healthcare markets offer attractive prospects and are growing continually. Our strategy for profitable growth is in place and we are successful both with our high-quality glass and plastic pharmaceutical primary packaging and with complex products like insulin pens, inhalers, autoinjectors and prefillable syringes. I am very optimistic for the future of our Company,” Röhrhoff said.